| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | ANX8 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human ANXA8 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与ANXA8抗体相关的文献摘要概括(基于公开文献信息整理)：
---
1. **标题**: "Annexin A8 as a potential biomarker for colorectal cancer progression"
**作者**: Wang Y, et al.
**摘要**: 研究通过免疫组化(使用ANXA8特异性抗体)发现ANXA8在结直肠癌组织中高表达，且与肿瘤侵袭性和不良预后相关，提示其可能作为诊断标志物。
2. **标题**: "Development and validation of a novel monoclonal antibody against human ANXA8 for functional studies"
**作者**: Müller J, et al.
**摘要**: 报道了一种新型ANXA8单克隆抗体的开发，验证其在Western blot、免疫荧光及流式细胞术中的特异性，并用于研究ANXA8在细胞膜修复中的作用机制。
3. **标题**: "Annexin A8 regulates leukemia cell proliferation via EGFR signaling pathway"
**作者**: Li X, et al.
**摘要**: 通过ANXA8抗体敲低实验发现，ANXA8通过调控EGFR信号通路影响白血病细胞增殖，为靶向治疗提供了潜在靶点。
---
注：以上文献信息为模拟概括，实际文献需通过PubMed或学术数据库检索确认。若需具体文章，建议提供研究领域细分(如癌症、免疫等)以便精准推荐。
The ANXA8 antibody targets Annexin A8 (ANXA8), a member of the annexin family of calcium-dependent phospholipid-binding proteins. Annexins are involved in diverse cellular processes, including membrane organization, vesicle trafficking, and cell signaling. ANXA8. specifically, is characterized by its unique N-terminal domain and calcium-dependent binding to cellular membranes. It is expressed in various tissues, with higher levels observed in the placenta, skin, and certain immune cells, and has been implicated in cell differentiation, apoptosis, and inflammatory responses.
Research on ANXA8 has highlighted its dual role in cancer. In some contexts, such as acute myeloid leukemia (AML) and pancreatic cancer, ANXA8 overexpression correlates with tumor progression, metastasis, and poor prognosis, suggesting its potential as a diagnostic or prognostic biomarker. Conversely, in other cancers like breast cancer, reduced ANXA8 expression has been linked to aggressive phenotypes, indicating context-dependent functions. ANXA8 antibodies are critical tools for studying these mechanisms, enabling detection of protein expression via techniques like immunohistochemistry (IHC), Western blotting (WB), and immunofluorescence (IF).
Commercially available ANXA8 antibodies are typically monoclonal or polyclonal, validated for specificity and sensitivity across applications. Recent studies also explore ANXA8's role in modulating the tumor microenvironment and chemoresistance, expanding its relevance in therapeutic targeting. However, variability in ANXA8 expression across cancer types underscores the need for further research to clarify its molecular interactions and clinical utility.
×
